Abstract
4-phenylbutyrate (PBA) is a small molecule that restores cognitive deficits in animal models of Alzheimer's disease (AD). Although the molecular basis of the cognitive benefits of PBA remains unknown, a multi-modal/multi-target mechanism has been proposed. Putative targets of this drug are different from those of drugs that are now used in clinical trials. As PBA is already administered to patients with congenital defects affecting enzymes in the urea cycle, it can be rapidly tested in AD clinical trials. However, the main drawback to its therapeutic use is the high dosage required (up to 15 g/day). Thus, deciphering the precise mechanism(s) of action of this drug may enable novel drugs with similar therapeutic effects to PBA to be developed that can be used at more manageable doses.
Keywords: Alzheimer's disease, chaperone, histone deacetylase, phenylbutyrate, amyloid and Tau, amyloid, Tau, 4-phenylbutyrate, multi-target mechanism, enzymes, therapeutic effects
Current Medicinal Chemistry
Title: Defining the Mechanism of Action of 4-Phenylbutyrate to Develop a Small-Molecule-Based Therapy for Alzheimers Disease
Volume: 18 Issue: 36
Author(s): M. Cuadrado-Tejedor, A. Garcia-Osta, A. Ricobaraza, J. Oyarzabal and R. Franco
Affiliation:
Keywords: Alzheimer's disease, chaperone, histone deacetylase, phenylbutyrate, amyloid and Tau, amyloid, Tau, 4-phenylbutyrate, multi-target mechanism, enzymes, therapeutic effects
Abstract: 4-phenylbutyrate (PBA) is a small molecule that restores cognitive deficits in animal models of Alzheimer's disease (AD). Although the molecular basis of the cognitive benefits of PBA remains unknown, a multi-modal/multi-target mechanism has been proposed. Putative targets of this drug are different from those of drugs that are now used in clinical trials. As PBA is already administered to patients with congenital defects affecting enzymes in the urea cycle, it can be rapidly tested in AD clinical trials. However, the main drawback to its therapeutic use is the high dosage required (up to 15 g/day). Thus, deciphering the precise mechanism(s) of action of this drug may enable novel drugs with similar therapeutic effects to PBA to be developed that can be used at more manageable doses.
Export Options
About this article
Cite this article as:
Cuadrado-Tejedor M., Garcia-Osta A., Ricobaraza A., Oyarzabal J. and Franco R., Defining the Mechanism of Action of 4-Phenylbutyrate to Develop a Small-Molecule-Based Therapy for Alzheimers Disease, Current Medicinal Chemistry 2011; 18 (36) . https://dx.doi.org/10.2174/092986711798347315
DOI https://dx.doi.org/10.2174/092986711798347315 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Biological and Clinical Implications of Clonal Heterogeneity and Clonal Evolution in Multiple Myeloma
Current Cancer Therapy Reviews Morphine as a Potential Oxidative Stress-Causing Agent
Mini-Reviews in Organic Chemistry TRAIL as Biomarker and Potential Therapeutic Tool for Cardiovascular Diseases
Current Drug Targets DNMT3B Promoter Polymorphisms and Risk of Late Onset Alzheimer’s Disease
Current Alzheimer Research Lipoxygenase Inhibitors as Cancer Chemopreventives: Discovery, Recent Developments and Future Perspectives
Current Medicinal Chemistry Pharmacokinetic and Pharmacogenetic Predictive Markers of Irinotecan Activity and Toxicity
Current Drug Metabolism The Role of Aryl Hydrocarbon Receptor-Regulated Cytochrome P450 Enzymes in Glioma
Current Pharmaceutical Design Structural Polymorphism of Amyloid Oligomers and Fibrils Underlies Different Fibrillization Pathways: Immunogenicity and Cytotoxicity
Current Protein & Peptide Science Human Platelets Express Authentic CB1 and CB2 Receptors
Current Neurovascular Research Glucocorticoid Regulates Parkin Expression in Mouse Frontal Cortex: Implications in Schizophrenia
Current Neuropharmacology Targeting the G2/M Transition for Antitumor Therapy
Letters in Drug Design & Discovery The Chemistry and Pharmacology of Genistein
The Natural Products Journal Natural Compounds as Antagonists of Canonical Wnt/β-Catenin Signaling
Current Chemical Biology Natural Products as Promising Drug Candidates for the Treatment of Alzheimer’s Disease: Molecular Mechanism Aspect
Current Neuropharmacology Snake Venom Proteins and Peptides as Novel Antibiotics Against Microbial Infections
Current Proteomics NMDA Receptors in Glial Cells: Pending Questions
Current Neuropharmacology Combining Bevacizumab with Radiation or Chemoradiation for Solid Tumors: A Review of the Scientific Rationale, and Clinical Trials
Current Angiogenesis (Discontinued) Gene Transfer to the Central Nervous System: Current State of the Art of the Viral Vectors
Current Genomics Drug Targets from Genetics: Alpha-Synuclein
CNS & Neurological Disorders - Drug Targets Ginkgo Biloba Extract (EGb 761) in Alzheimers Disease: Is there Any Evidence?
Current Alzheimer Research